{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:43:46Z","timestamp":1785797026920,"version":"3.56.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,7]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitors (TKIs) are standard therapy for patients with chronic myeloid leukemia. Each of these drugs has a specific profile of tyrosine kinases that they inhibit and, although all are clinically effective, they each have unique toxicity profiles. With the introduction of ponatinib, arterio-occlusive events were first noted and later found to occur with all TKIs to various extents. The recognition of this \u201cclass effect\u201d was delayed considering ponatinib was introduced 10 years after the introduction of imatinib. The reasons for the delay in identification of this class effect are likely multifaceted. Importantly, there is an inconsistency in adverse event reporting criteria among the major clinical trials of the various TKIs, likely resulting in mixed reporting of arterio-occlusive events. Reporting events based on a frequency threshold, lack of sufficient follow-up, attempts at causality attribution, and the primary focus on molecular response may all have played an additional role. Considering the increasing rate of arterio-occlusive events over time, the termination of many trials after only 5 years prevents full assessment of the impact of these events. A comprehensive evaluation of TKI adverse effects using uniform Medical Dictionary for Regulatory Activities terms and comprehensive adjudication of these events may be helpful in better assessing the real risk for patients with each TKI. Future clinical trials should use a uniform and comprehensive approach to reporting adverse events without attempting to assign causality to the study drug.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022403","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T22:15:49Z","timestamp":1704838549000},"page":"858-865","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0194-5512","authenticated-orcid":false,"given":"Lukas","family":"Veltmaat","sequence":"first","affiliation":[{"name":"1Medical College of Georgia, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"2Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2024030716203779000_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024030716203779000_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/asheducation-2018.1.161","article-title":"The argument for using imatinib in CML","volume":"2018","author":"Claudiani","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"19","key":"2024030716203779000_bib3","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024030716203779000_bib4","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024030716203779000_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy\u00a0in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"2024030716203779000_bib6","unstructured":"US Food and Drug Administration\n          . FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. Updated 20 December 2013. Accessed 18 November 2023. http:\/\/wayback.archive-it.org\/7993\/20161022203734\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm373040.htm#safety."},{"issue":"4","key":"2024030716203779000_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2024030716203779000_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"2024030716203779000_bib9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2024030716203779000_bib10","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2024030716203779000_bib11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024030716203779000_bib12","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024030716203779000_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024030716203779000_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2024030716203779000_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024030716203779000_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"20","key":"2024030716203779000_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024030716203779000_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2024030716203779000_bib19","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2024030716203779000_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"2024030716203779000_bib21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2024030716203779000_bib22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"24","key":"2024030716203779000_bib23","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024030716203779000_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"issue":"21","key":"2024030716203779000_bib25","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A\u00a0phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024030716203779000_bib26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cancers12051242","article-title":"Long-term survival, vascular occlusive events and efficacy biomarkers of first-Line treatment of CML: a meta-analysis","volume":"12","author":"Haguet","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024030716203779000_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"2024030716203779000_bib28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2024030716203779000_bib29","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2024030716203779000_bib30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2024030716203779000_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024030716203779000_bib32","unstructured":"Cancer Therapy Evaluation Program\n          . Common terminology criteria for adverse events v3.0. 2006. Accessed 18 November 2023. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"2024030716203779000_bib33","unstructured":"Medical Directory for Regulatory Activities. 2023. Accessed 18 November 2023. https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy."},{"key":"2024030716203779000_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical\u00a0trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"12","key":"2024030716203779000_bib35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2024030716203779000_bib36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.clml.2017.06.011","article-title":"Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based Oncology Practices in the United States","volume":"17","author":"Coutinho","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2024030716203779000_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01221-z","article-title":"Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee","volume":"15","author":"Januzzi","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"21","key":"2024030716203779000_bib38","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024030716203779000_bib39","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/leu.2017.247","article-title":"Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results","volume":"31","author":"Hughes","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2024030716203779000_bib40","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","article-title":"Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib","volume":"100","author":"Caocci","year":"2021","journal-title":"Ann Hematol"},{"issue":"22","key":"2024030716203779000_bib41","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2024030716203779000_bib42","first-page":"330","article-title":"Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia","volume":"76","author":"Fiets","year":"2018","journal-title":"Neth J Med"},{"issue":"5","key":"2024030716203779000_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quintas-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2024030716203779000_bib44","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2024030716203779000_bib45","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/bloodadvances.2020002644","article-title":"Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine","volume":"4","author":"Wu","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024030716203779000_bib46","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1055\/s-0039-1688787","article-title":"Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response","volume":"119","author":"Hamadi","year":"2019","journal-title":"Thromb Haemost"},{"issue":"2","key":"2024030716203779000_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024030716203779000_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"2024030716203779000_bib49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","article-title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"113","author":"Lee","year":"2021","journal-title":"Int J Hematol"},{"issue":"7","key":"2024030716203779000_bib50","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/MCB.01454-13","article-title":"The capable ABL: what is its biological function?","volume":"34","author":"Wang","year":"2014","journal-title":"Mol Cell Biol"},{"issue":"Supplement 1","key":"2024030716203779000_bib51","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2022-157822","article-title":"Three-year update from the optic trial: a dose-optimization study of 3 starting doses of ponatinib","volume":"140","author":"Cortes","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024030716203779000_bib52","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00277-021-04507-x","article-title":"Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry","volume":"100","author":"Devos","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"2024030716203779000_bib53","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-018-3337-2","article-title":"Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice","volume":"97","author":"Breccia","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2024030716203779000_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-023-00891-x","article-title":"Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events","volume":"13","author":"Abdelmagid","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022403\/2217069\/blood_bld-2023-022403-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022403\/2217069\/blood_bld-2023-022403-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T16:21:59Z","timestamp":1709828519000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/10\/858\/507074\/Arterio-occlusive-events-among-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,3,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022403","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}